Get Premium to unlock powerful stock data
Inozyme Pharma Inc logo

Inozyme Pharma Inc

$ 3.97 +0.03 (+0.76%) 10:08 PM EST
P/E:
At Loss
P/B:
1.04
Market Cap:
$ 159.19M
Enterprise V:
$ 63.40M
Volume:
75.94K
Avg Vol (2M):
306.91K
Volume:
75.94K
Market Cap $:
159.19M
PE Ratio:
At Loss
Avg Vol (2-Month):
306.91K
Enterprise Value $:
63.40M
PB Ratio:
1.04
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%

Business Description

Inozyme Pharma Inc
NAICS : 541714 SIC : 2834
321 Summer Street, Suite 400, Boston, MA, USA, 02210
Description
Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies.
Name Current Vs Industry Vs History
Cash-To-Debt 30.61
Equity-to-Asset 0.87
Debt-to-Equity 0.03
Debt-to-EBITDA -0.05
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0
Distress
Grey
Safe
Beneish M-Score 0
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate -46
3-Year EPS without NRI Growth Rate -73.4
3-Year FCF Growth Rate -47.6

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 40.97
9-Day RSI 45.14
14-Day RSI 45.91
6-1 Month Momentum % -48.25
12-1 Month Momentum % -75.8

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 8.2
Quick Ratio 8.2
Cash Ratio 7.97

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -16.1
Name Current Vs Industry Vs History
ROE % -50.64
ROA % -46.1
ROIC % -687.83
ROC (Joel Greenblatt) % -1344.31
ROCE % -49.55

Financials (Next Earnings Date:2022-08-11 Est.)

INZY's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:INZY

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Performance
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0
EPS (TTM) ($) -2.63
Beta 0
Volatility % 34.39
14-Day RSI 45.91
14-Day ATR ($) 0.383267
20-Day SMA ($) 4.018
12-1 Month Momentum % -75.8
52-Week Range ($) 3.54 - 19.58
Shares Outstanding (Mil) 40.1

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Inozyme Pharma Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More